Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease

NCT04991831 is registered in ClinicalTrials.gov with InSightec as lead sponsor.

NCT NCT04991831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04991831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease
Lead sponsor
InSightec
Phase
Observational
Overall status
Recruiting
Start date
April 28, 2022
Completion date
December 31, 2027
Enrollment
50 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

tremor associated with tremor dominant parkinson's disease